FG-4592, a kind of prolyl hydroxylase inhibitor, has been used as a pretreatment to attenuate AKI through anti-oxidative stress in our previous study by increasing the levels of HIF-1α at the acute phase (Li et al., 2020); however, inhibition of HIF-1α mRNA was observed (data not shown) at the same time, which may be related to negative feedback. Here, HIF1A is linked to acute kidney injury.